Skip to main content
Fig. 1 | BMC Psychiatry

Fig. 1

From: Dispensation of attention deficit hyperactivity disorder (ADHD) medications in patients receiving opioid agonist therapy; a national prospective cohort study in Norway from 2015 to 2017

Fig. 1

Doses of dispensed ADHD medication among patients who received OAT opioids from 2015 to 2017. Legends: ADHD = Attention deficit hyperactivity disorder, ADHD medication = atomoxetine, racemic amphetamine, dexamphetamine, lisdexamphetamine, and methylphenidate, CI = confidence interval, and Df = degrees of freedom. 1) Paired-samples t-test, df = 87, 2) Paired-samples t-test, df = 79, 3) Paired-samples t-test, df = 10, 4) Paired-samples t-test, df = 26, 5) Paired-samples t-test, df = 5, and 6) Paired-samples t-test, df = 4. * = Upper recommended doses according to The European Medicines Agency (EMA) per July 2019, ** = Calculation of the differences in mean daily doses between 2015 and 2017, *** = Upper recommended daily dose of short- and intermediate-acting methylphenidate according to the EMA, and **** = Include short- and intermediate-acting methylphenidate (tablets or capsules), not depot formulations. The figure displays the mean daily doses of each dispensed ADHD medication among patients who were dispensed at least one dispensation ADHD medication and OAT opioid, respectively, each calendar year in the study period from 2015 to 2017

Back to article page

BMC Psychiatry

ISSN: 1471-244X

Contact us